We are making nanopumps based on technology we developed at NASA. We are 100x smaller, 10x more accurate, and 10x less expensive than today's best injectable drug delivery engine.
Current Status
JDRF awarded us a $1.5M grant. Strong, continued and growing interest from key decision makers at 3 biopharma organizations and 1 electronic drug delivery OEM.
Problem or Opportunity
Injectable therapies are inconvenient.
Over the last 4 years, the FDA has approved more injectable therapies than oral therapies. Supercomputers are accelerating the design of large-molecule drugs ideal for cancer and chronic disease. However, it is unreasonable to imagine a reality where living longer and healthier requires multiple syringes, multiple times a day.
Solution (product or service)
A nanopatch based on technology we developed at NASA that is less expensive and at least 5 times smaller than the best today. Initially, we will start with the most inconvenient therapy, insulin injection for diabetes, and use our nanopatch to enable individuals to safely ignore type 1 diabetes for 3 days at a time. Later, we will bring multiple therapies on the same patch to further reduce the burden of injectable therapies
Business model
Market the nanopatch to biopharma for combination drug products. (B2B) Market the nanopatch to endocrinologists for individuals injecting insulin (B2B2C)
